Otezla Alternatives Compared
| Otezla (apremilast) | Cosentyx (secukinumab) | Skyrizi (risankizumab) |
|
|---|
| Otezla (apremilast) | Cosentyx (secukinumab) | Skyrizi (risankizumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Otezla is a PDE4 inhibitor that may be used to treat adults with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s Disease. It may also be used to treat plaque psoriasis... View more |
Prescription only
Cosentyx may be used to treat plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa (HS), and some other conditions. After an initial loading dose, Cosentyx can be... View more |
Prescription only
Skyrizi is an interleukin inhibitor that may be used to treat adults with plaque psoriasis, psoriatic arthritis, Crohn's disease, or ulcerative colitis (UC). The usual dosage is 150mg every 12 weeks... View more |
Related suggestions |
|||||||||||||||||||||||
| More about Otezla (apremilast) | More about Cosentyx (secukinumab) | More about Skyrizi (risankizumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Otezla has an average rating of 5.2 out of 10 from a total of 442 ratings on Drugs.com. 35% of reviewers reported a positive effect, while 40% reported a negative effect. |
Cosentyx has an average rating of 6.3 out of 10 from a total of 252 ratings on Drugs.com. 52% of reviewers reported a positive effect, while 31% reported a negative effect. |
Skyrizi has an average rating of 7.9 out of 10 from a total of 59 ratings on Drugs.com. 73% of reviewers reported a positive effect, while 14% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Otezla side effects |
View all Cosentyx side effects |
View all Skyrizi side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Otezla prices |
View all Cosentyx prices |
View all Skyrizi prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
9 hours |
744 hours |
672 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 111 drugs are known to interact with Otezla:
|
A total of 251 drugs are known to interact with Cosentyx:
|
A total of 190 drugs are known to interact with Skyrizi:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
March 21, 2014 |
January 21, 2015 |
April 23, 2019 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Stelara
Stelara (ustekinumab) is used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and ...
Cosentyx
Cosentyx (secukinumab) is used to treat plaque psoriasis, psoriatic arthritis, ankylosing ...
Skyrizi
Skyrizi (risankizumab) is used to treat plaque psoriasis, psoriatic arthritis, ulcerative colitis ...
Humira
Humira is a tumor necrosis factor blocker used to treat many inflammatory conditions in adults ...
Ilumya
Ilumya (tildrakizumab) is used to treat moderate-to-severe plaque psoriasis to reduce plaques ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Tremfya
Tremfya (guselkumab) injection is used to treat plaque psoriasis, psoriatic arthritis, ulcerative ...
Enbrel
Enbrel is used to treat rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Learn about ...
Remicade
Remicade is used to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn's ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.